Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Prognostic factors in patients with pathological stage I non-seminomatous testicular germ cell tumors and tumor recurrence during follow-up

  • 20 Accesses

  • 2 Citations

Abstract

Clinical staging in patients with stage I nonseminomatous germ cell tumors (NSGCTs) of the testis fails in 30% to correctly assess pathological stage since microscopic and small-volume retroperitoneal disease is not detectable on computed tomography of the abdomen. Patients staged by retroperitoneal lymph node dissection as pathological stage I incur a distant (chest or serological) tumor relapse rate of 7–15% during follow-up. Recently, we reported on new risk factors as predictors of pathological stage by flow cytometric DNA analysis in clinical stage I patients. These same methods were applied to a group of 14 pathological stage I patients who subsequently had either chest or serological recurrence. The findings in this group of patients were compared with those in a group of 47 pathological stage I patients who did not experience recurrence. In pathological stage I NSGCT patients with distant (chest or serological) tumor relapse, we found by histological evaluation and DNA analysis of the original orchiectomy specimen proliferative tumor activity to be significantly predictive of relapse. Much as proliferative activity of the primary tumor is predictive of retroperitoneal metastasis, it may be a predictor of recurrence in pathological stage I patients.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    DeRiese WT, Albers P, Walker EB, Ulbright TM, Crabtree WN, Reister T, Foster RS, Donohue JP (1994) Predictive parameters of biologic behavior of early stage nonseminomatous testicular germ cell tumors. Cancer 74:1335

  2. 2.

    Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R (1993) Primary retroperitoneal lymph node dissection in clinical stage A nonseminomatous germ cell testis cancer. Br J Urol 71:326

  3. 3.

    Freedman LS, Parkinson MC, Jones WG, Oliver RTD, Peckham MJ, Read G, Newlands ES, Williams CJ (1987) Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchiectomy alone. Lancet II:294

  4. 4.

    Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA (1983) Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 31:1333

  5. 5.

    Klepp O, Olsson AM, Henrikson H, Aass N, Dahl O, Stenwig AE, Persson B-E, Cavallin-Stahl E, Fossa SD, Wahlqvist L (1990) Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. J Clin Oncol 8:509

  6. 6.

    Moul JW, McCarthy WF, Fernandez EB, Sesterhenn IA (1994) Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer. Cancer Res 54:362

  7. 7.

    Read G, Stenning SP, Cullen MH, Parkinson MC, Horwich A, Kaye SB, Cook PA (1992) Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 10:1762

Download references

Author information

Correspondence to P. Albers.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Albers, P., DeRiese, W.T., Ulbright, T.M. et al. Prognostic factors in patients with pathological stage I non-seminomatous testicular germ cell tumors and tumor recurrence during follow-up. Urol. Res. 23, 211–213 (1995). https://doi.org/10.1007/BF00393300

Download citation

Key words

  • Non-seminomatous testicular germ cell tumors
  • Tumor recurrence
  • Prognostic parameters
  • Flow cytometry